Synergistic anticancer effect by targeting CDK2 and EGFR–ERK signaling
Journal of Cell Biology · 01.01.2024 · 223 (1)
DOI: 10.1083/jcb.202203005 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cell Biology, online erschienen am 13.11.2023. Verfasst von Jinhuan Wu und 20 weiteren Autor:innen. Beteiligte Einrichtung: Research Center for Translational Medicine, East Hospital, Tongji University School of Medicine, Shanghai, China. Hauptthemen laut MEDLINE: MAP Kinase Signaling System, Signal Transduction, Neoplasms. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-SA 4.0). Gefördert von: National Key R&D Program of China, National Natural Science Foundation of China, Shanghai Pujiang program.
Abstract (Originalsprache)
The EGFR-RAS-ERK pathway is one of the most important signaling cascades in cell survival, growth, and proliferation. Aberrant activation of this pathway is a common mechanism in various cancers. Here, we report that CDK2 is a novel regulator of the ERK pathway via USP37 deubiquitinase (DUB). Mechanistically, CDK2 phosphorylates USP37, which is required for USP37 DUB activity. Further, USP37 deubiquitinates and stabilizes ERK1/2, thereby enhancing cancer cell proliferation. Thus, CDK2 is able to promote cell proliferation by activating USP37 and, in turn, stabilizing ERK1/2. Importantly, combined CDK1/2 and EGFR inhibitors have a synergetic anticancer effect through the downregulation of ERK1/2 stability and activity. Indeed, our patient-derived xenograft (PDX) results suggest that targeting both ERK1/2 stability and activity kills cancer cells more efficiently even at lower doses of these two inhibitors, which may reduce their associated side effects and indicate a potential new combination strategy for cancer therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Research Center for Translational Medicine, East Hospital, Tongji University School of Medicine, Shanghai, China.
- Department of Biochemistry and Molecular Biology, Tongji University School of Medicine, Shanghai, China.
- School of Pharmacy, Wenzhou Medical University, Wenzhou, China.
- Shanghai Yangzhi Rehabilitation Hospital (Shanghai Sunshine Rehabilitation Center), Tongji University School of Medicine, Shanghai, China.
- Tongji University Cancer Center, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, China.
- Clinical and Translational Research Center of Shanghai First Maternity and Infant Hospital, Shanghai Key Laboratory of Signaling and Disease Research, Frontier Science Center for Stem Cell Research, School of Life Scien…
ORCID-Profile: Jinhuan Wu, Yuping Chen, Rui Li, Yaping Guan, Mu Chen, Hui Yin, Xiaoning Yang, Mingpeng Jin, Bingsong Huang, Xin Ding, Jie Yang, Zhe Wang, Yiming He, Qianwen Wang, Jian Luo, Ping Wang, Zhiyong Mao, Michael S Y Huen, Zhenkun Lou, Jian Yuan, Fanghua Gong
Förderung
- National Key R&D Program of China
- National Natural Science Foundation of China
- Shanghai Pujiang program
- China Postdoctoral Science Foundation
- Natural Science Foundation of Shanghai Municipality
- Shanghai Municipal Health Commission
- Chinese Academy of Medical Sciences
Zitieren
APA
Wu, J., Chen, Y., Li, R., Guan, Y., Chen, M., Yin, H., Yang, X., Jin, M., Huang, B., Ding, X., Yang, J., Wang, Z., He, Y., Wang, Q., Luo, J., Wang, P., Mao, Z., Huen, M. S. Y., Lou, Z., …, & Gong, F. (2024). Synergistic anticancer effect by targeting CDK2 and EGFR–ERK signaling. Journal of Cell Biology, 223(1). https://doi.org/10.1083/jcb.202203005
Vancouver
Wu J, Chen Y, Li R, Guan Y, Chen M, Yin H, et al. Synergistic anticancer effect by targeting CDK2 and EGFR–ERK signaling. Journal of Cell Biology. 2024;223(1). doi:10.1083/jcb.202203005
BibTeX
@article{Wu2024,
author = {Wu, Jinhuan and Chen, Yuping and Li, Rui and Guan, Yaping and Chen, Mu and Yin, Hui and Yang, Xiaoning and Jin, Mingpeng and Huang, Bingsong and Ding, Xin and Yang, Jie and Wang, Zhe and He, Yiming and Wang, Qianwen and Luo, Jian and Wang, Ping and Mao, Zhiyong and Huen, Michael S Y and Lou, Zhenkun and Yuan, Jian and Gong, Fanghua},
title = {Synergistic anticancer effect by targeting CDK2 and EGFR–ERK signaling},
journal = {Journal of Cell Biology},
year = {2024},
volume = {223},
number = {1},
doi = {10.1083/jcb.202203005}
}
EUVIMED